Dementia Incidence Continues to Increase with Age in the Oldest Old The 90+Study

Department of Neurology, University of California, Irvine, CA 92697-1400, USA.
Annals of Neurology (Impact Factor: 11.91). 01/2010; 67(1):114-21. DOI: 10.1002/ana.21915
Source: PubMed

ABSTRACT The oldest old are the fastest growing segment of the US population, and accurate estimates of dementia incidence in this group are crucial for healthcare planning. Although dementia incidence doubles every 5 years from ages 65 to 90 years, it is unknown if this exponential increase continues past age 90 years. Here, we estimate age- and sex-specific incidence rates of all-cause dementia in people aged 90 years and older, including estimates for centenarians.
Participants are from The 90+ Study, a population-based longitudinal study of aging and dementia. Three hundred thirty nondemented participants aged 90 years and older at baseline were followed between January 2003 and December 2007. Age- and sex-specific incidence rates of all-cause dementia were estimated by person-years analysis.
The overall incidence rate of all-cause dementia was 18.2% (95% confidence interval [CI], 15.3-21.5) per year and was similar for men and women (risk ratio, 0.94; 95% CI, 0.65-1.37). Rates increased exponentially with age from 12.7% per year in the 90-94-year age group, to 21.2% per year in the 95-99-year age group, to 40.7% per year in the 100+-year age group. The doubling time based on a Poisson regression was 5.5 years.
Incidence of all-cause dementia is very high in people aged 90 years and older and continues to increase exponentially with age in both men and women. Projections of the number of people with dementia should incorporate this continuing increase of dementia incidence after age 90 years. Our results foretell the growing public health burden of dementia in an increasingly aging population.

Download full-text


Available from: María M Corrada, Jun 20, 2014
  • Source
    • "A lzheimer's disease (AD) is the pathological cause of the most common dementia in the world, and as many as 50% of people older than age 85 may be afflicted (Corrada et al., 2010; Evans et al., 1989; Fitzpatrick et al., 2004). The diagnostic hallmarks of AD are neurofibrillary tangles and amyloid plaques that are easily identified in postmortem examination (Braak and Braak, 1991), and more recently with in vivo brain imaging techniques (Frisoni et al., 2013). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Although progressive functional brain network disruption has been one of the hallmarks of Alzheimer's Disease, little is known about the origin of this functional impairment that underlies cognitive symptoms. We investigated how the loss of white matter (WM) integrity disrupts the organization of the functional networks at different frequency bands. The analyses were performed in a sample of healthy elders and mild cognitive impairment (MCI) subjects. Spontaneous brain magnetic activity (measured with magnetoencephalography) was characterized with phase synchronization analysis, and graph theory was applied to the functional networks. We identified WM areas (using diffusion weighted MRI) that showed a statistical dependence between the fractional anisotropy and the graph metrics. These regions are part of an episodic memory network, and were also related to cognitive functions. Our data support the hypothesis that disruption of the anatomical networks influences the organization at the functional level resulting in the prodromal dementia syndrome of MCI.
    03/2014; DOI:10.1089/brain.2013.0208
  • Source
    • "Some studies have reported that incidence levels slow down after an age of 90 years (Miech et al., 2002), but these findings remain controversial. A recent analysis indicated that dementia incidence may continue to increase and that previous observations of a plateau may be due to sparse data for the oldest-old (Corrada et al., 2010). The economic impact of dementia is already enormous with total costs of more than s177 billion in Europe solely in 2008 (Wimo et al., 2011). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Alzheimer's disease (AD) is a fast growing world-wide epidemic. AD is a genetically complex, slowly progressive, and irreversible neurodegenerative disease of the brain. During decades of asymptomatic progression multiple interactive systems, pathways and molecular mechanisms (e.g. protein processing, aberrant signaling, inflammation and immune system, lipid transport, endocytosis, apoptosis, oxidative damage and response to stress, tau pathology, neuron and synapse loss, energy metabolism), contribute to the development of the early clinical prodromal stage with episodic memory deficits and to further decline and loss of general cognitive functioning during the final syndromal dementia stage. The non-mendelian genetically complex "sporadic" AD type is the most common form of dementia affecting people usually over the age of 65. Despite considerable progress of AD research in recent years and evolving paradigm shifts in both pathophysiological concepts as well as in diagnostic criteria fundamental challenges have not yet been resolved. The strong age-related incidence, the recent failure and complete lack of disease-modifying or preventive therapy that may delay onset or substantially affect the pathophysiology of AD, result in an enormous burden posed both on individuals, their families and care givers, and the societies at large, and these call for urgent concerted worldwide measures. Based on the meeting of the German Task Force on Alzheimer's Disease (GTF-AD) in Paris on July 19th 2011, the present position paper provides an overview on the current state and future developments in epidemiology, pathophysiology, disease conceptualization, diagnostic criteria and their use in research and clinical practice, as well as preventive and symptomatic therapeutic approaches. Particular emphasis is placed on a discussion of the different approaches to diagnostics and therapy taken by preventive/public health medicine, methodologically advanced academic research propagating the use of sophisticated biomarkers, and everyday clinical practice focusing on patient-centered care. During the next 10 years, major advances both in early detection as well as in therapy and comprehensive AD care seem mandatory. These still unmet needs call for ever more concerted and focused efforts in research across the world to combat the erupting and as yet uncontrolled epidemic of AD.
    Progress in Neurobiology 12/2011; 95(4):718-28. DOI:10.1016/j.pneurobio.2011.11.008 · 10.30 Impact Factor
  • Source
    • "In people over age 90 years, the fastest growing segment in the US population, the prevalence of dementias was estimated as 28% in men and 45% in women, with doubling every 5 years only for women [32]. In the oldest-olds incidence of dementia continues to increase exponentially with age in both men and women up to 40.7% per year in the 100+ age group [33]. In USA, dementia prevalence increased with age from 5% in the 8 th decade to 37.4% in those aged 95+ [34], while AD affects almost 50% of the adults over 85 years [35]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: There are several consensus criteria for both the clinical and neuropathological diagnosis of different types of dementias. The clinical diagnostic accuracy using revised research criteria and newly developed biomarkers (MRI, PET, CSF analysis, genetic markers) ranges from 65 to 96% (for Alzheimer disease) with a specificity of diagnostic criteria versus other dementias of 23-88%. Neuropathological assessment of dementing disorders using immunohistochemistry, molecular biologic and genetic methods can achieve a diagnosis/classification, based on the homogeneous definitions, harmonized inter-laboratory methods and standards for the assessment of nervous system lesions, in about 99%, without, however, being able to clarify the causes/etiology of most of these disorders. Further prospective and concerted clinicopathological studies using revised methodological and validated protocols and uniform techniques are required to establish the nature, distribution pattern and grades of lesions and; thus, to overcome the limitations of the current diagnostic framework. By data fusion this my allow their more uniform application and correlation with the clinical data in order to approach a diagnostic "gold standard", and to create generally accepted criteria for differentiating cognitive disorders from healthy brain aging. The detection of disease-specific pathologies will be indispensable to determinate the efficacy of new therapy options.
    Acta Neuropathologica 01/2009; 117(2):101-10. DOI:10.1007/s00401-008-0466-z · 9.78 Impact Factor
Show more